vs
Side-by-side financial comparison of PROSPERITY BANCSHARES INC (PB) and Bio-Techne (TECH). Click either name above to swap in a different company.
PROSPERITY BANCSHARES INC is the larger business by last-quarter revenue ($367.6M vs $295.9M, roughly 1.2× Bio-Techne). PROSPERITY BANCSHARES INC runs the higher net margin — 31.6% vs 12.8%, a 18.8% gap on every dollar of revenue. Over the past eight quarters, PROSPERITY BANCSHARES INC's revenue compounded faster (19.2% CAGR vs 4.2%).
Prosperity Bancshares, Inc. is a bank holding company headquartered in Houston, Texas with operations in Texas and central Oklahoma. As of December 31, 2019, the company operated 285 branches: 65 in the Houston area, including The Woodlands, Texas; 30 in South Texas, including Corpus Christi, Texas and Victoria, Texas; 75 in the Dallas–Fort Worth metroplex; 22 in East Texas; 29 in Central Texas, including Austin, Texas and San Antonio; 34 in West Texas, including Lubbock, Texas, Midland–Odess...
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
PB vs TECH — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $367.6M | $295.9M |
| Net Profit | $116.3M | $38.0M |
| Gross Margin | — | 64.6% |
| Operating Margin | — | 18.4% |
| Net Margin | 31.6% | 12.8% |
| Revenue YoY | — | -6.4% |
| Net Profit YoY | -10.7% | 68.3% |
| EPS (diluted) | $1.16 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $367.6M | — | ||
| Q4 25 | $275.0M | $295.9M | ||
| Q3 25 | $273.4M | — | ||
| Q2 25 | $267.7M | $317.0M | ||
| Q1 25 | $265.4M | $316.2M | ||
| Q4 24 | $267.8M | $297.0M | ||
| Q3 24 | $261.7M | $289.5M | ||
| Q2 24 | $258.8M | $306.1M |
| Q1 26 | $116.3M | — | ||
| Q4 25 | $139.9M | $38.0M | ||
| Q3 25 | $137.6M | — | ||
| Q2 25 | $135.2M | $-17.7M | ||
| Q1 25 | $130.2M | $22.6M | ||
| Q4 24 | $130.1M | $34.9M | ||
| Q3 24 | $127.3M | $33.6M | ||
| Q2 24 | $111.6M | $40.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% |
| Q1 26 | — | — | ||
| Q4 25 | 65.1% | 18.4% | ||
| Q3 25 | 64.4% | — | ||
| Q2 25 | 64.3% | -7.5% | ||
| Q1 25 | 62.7% | 12.2% | ||
| Q4 24 | 62.0% | 16.0% | ||
| Q3 24 | 62.1% | 13.8% | ||
| Q2 24 | 55.2% | 15.0% |
| Q1 26 | 31.6% | — | ||
| Q4 25 | 50.9% | 12.8% | ||
| Q3 25 | 50.3% | — | ||
| Q2 25 | 50.5% | -5.6% | ||
| Q1 25 | 49.1% | 7.1% | ||
| Q4 24 | 48.6% | 11.7% | ||
| Q3 24 | 48.6% | 11.6% | ||
| Q2 24 | 43.1% | 13.3% |
| Q1 26 | $1.16 | — | ||
| Q4 25 | $1.48 | $0.24 | ||
| Q3 25 | $1.45 | — | ||
| Q2 25 | $1.42 | $-0.11 | ||
| Q1 25 | $1.37 | $0.14 | ||
| Q4 24 | $1.36 | $0.22 | ||
| Q3 24 | $1.34 | $0.21 | ||
| Q2 24 | $1.17 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $172.9M |
| Total DebtLower is stronger | — | $260.0M |
| Stockholders' EquityBook value | $8.2B | $2.0B |
| Total Assets | $43.6B | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $172.9M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $162.2M | ||
| Q1 25 | — | $140.7M | ||
| Q4 24 | — | $177.5M | ||
| Q3 24 | — | $187.5M | ||
| Q2 24 | — | $152.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M |
| Q1 26 | $8.2B | — | ||
| Q4 25 | $7.6B | $2.0B | ||
| Q3 25 | $7.7B | — | ||
| Q2 25 | $7.6B | $1.9B | ||
| Q1 25 | $7.5B | $2.0B | ||
| Q4 24 | $7.4B | $2.1B | ||
| Q3 24 | $7.4B | $2.1B | ||
| Q2 24 | $7.3B | $2.1B |
| Q1 26 | $43.6B | — | ||
| Q4 25 | $38.5B | $2.5B | ||
| Q3 25 | $38.3B | — | ||
| Q2 25 | $38.4B | $2.6B | ||
| Q1 25 | $38.8B | $2.6B | ||
| Q4 24 | $39.6B | $2.7B | ||
| Q3 24 | $40.1B | $2.7B | ||
| Q2 24 | $39.8B | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PB
| Net Interest Income | $321.1M | 87% |
| Noninterest Income | $46.5M | 13% |
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
